Loading...
•
Mar 31, 2022
Replimune Q4 2022 Earnings Report
Announced financial results for the fiscal fourth quarter and year ended March 31, 2022 and provided a business update.
Key Takeaways
Replimune reported their Q4 2022 financial results and corporate update, ending the fiscal year in a strong position. They are maintaining guidance to complete enrollment into the CERPASS clinical trial in CSCC mid-year and to release top line data in early 2023. Initial directional data from the IGNYTE clinical trial in anti-PD1 failed melanoma is expected in late 2022.
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) is expected to be completed in mid-year 2022; top line data expected Q1 2023.
Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in anti-PD1 failed melanoma is expected in late 2022.
Phase 2 development plan for RP2/RP3 in HCC, CRC and SCCHN announced.
Existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.
Forward Guidance
Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...